Marisa Wexler, MS, senior science writer —

Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.

Articles by Marisa Wexler

Orladeyo approved in Peru as preventive HAE treatment

The oral medication Orladeyo (berotralstat) is now approved in Peru as a prophylactic, or preventive, treatment to reduce the risk of swelling attacks in people with hereditary angioedema (HAE), ages 12 and older. The approval from Peru’s General Directorate of Medicines, Supplies and Drugs comes just months after…

Orladeyo approved in Brazil for HAE patients 12 and older

The once-daily oral therapy Orladeyo (berotralstat) has been approved in Brazil to prevent swelling attacks in people, 12 and older, with hereditary angioedema (HAE). The approval by the Brazilian Health Regulatory Agency (ANVISA) makes Orladeyo the first oral prophylactic (preventive) therapy authorized for HAE patients in the country.

STAR-0215 reduces HAE attacks over 90% in early trial, data show

Treatment with the experimental under-the-skin injection therapy STAR-0215 reduced the rates of monthly swelling attacks by more than 90% in people with hereditary angioedema (HAE) in a small early clinical trial. That’s according to new data announced by developer Astria Therapeutics, which further showed that HAE attacks…

Sebetralstat moves toward early access treatment for HAE in UK

The U.K. Medicines and Healthcare products Regulatory Agency (MHRA) has awarded promising innovative medicine designation to sebetralstat, an experimental oral therapy KalVista Pharmaceuticals is developing as an on-demand treatment to resolve swelling attacks in hereditary angioedema (HAE). The designation is the first step in the Early Access…